These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18251495)

  • 21. Synthesis and biological action of some pyrido-[1,3]-diazepine and pyrido-[2, 3-d]-pyrimidine derivatives.
    Sołoducho J; Mrozikiewicz A; Bobkiewicz-Kozłowska T
    Pol J Pharmacol Pharm; 1983; 35(2):131-7. PubMed ID: 6622296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.
    Gege C; Bao B; Bluhm H; Boer J; Gallagher BM; Korniski B; Powers TS; Steeneck C; Taveras AG; Baragi VM
    J Med Chem; 2012 Jan; 55(2):709-16. PubMed ID: 22175799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.
    Huang H; Hutta DA; Hu H; DesJarlais RL; Schubert C; Petrounia IP; Chaikin MA; Manthey CL; Player MR
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2355-61. PubMed ID: 18342505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
    Li H; Anderes KL; Kraynov EA; Luthin DR; Do QQ; Hong Y; Tompkins E; Sun ET; Rajapakse R; Pathak VP; Christie LC; Feng J; Vazir H; Castillo R; Gregory ML; Castro M; Nared-Hood K; Paderes G; Anderson MB
    J Med Chem; 2006 Jun; 49(11):3362-7. PubMed ID: 16722655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Apr; 20(7):2369-75. PubMed ID: 22365911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of pyrido[1,2-α]pyrimidine-4-ones as new molecules improving the transcriptional functions of estrogen-related receptor α.
    Peng L; Gao X; Duan L; Ren X; Wu D; Ding K
    J Med Chem; 2011 Nov; 54(21):7729-33. PubMed ID: 21958216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.
    Matulenko MA; Paight ES; Frey RR; Gomtsyan A; DiDomenico S; Jiang M; Lee CH; Stewart AO; Yu H; Kohlhaas KL; Alexander KM; McGaraughty S; Mikusa J; Marsh KC; Muchmore SW; Jakob CL; Kowaluk EA; Jarvis MF; Bhagwat SS
    Bioorg Med Chem; 2007 Feb; 15(4):1586-605. PubMed ID: 17197188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
    Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
    Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists.
    Wang X; Kolasa T; El Kouhen OF; Chovan LE; Black-Shaefer CL; Wagenaar FL; Garton JA; Moreland RB; Honore P; Lau YY; Dandliker PJ; Brioni JD; Stewart AO
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4303-7. PubMed ID: 17532216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of CYT997: a structurally novel orally active microtubule targeting agent.
    Burns CJ; Harte MF; Bu X; Fantino E; Joffe M; Sikanyika H; Su S; Tranberg CE; Wilson N; Charman SA; Shackleford DM; Wilks AF
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4639-42. PubMed ID: 19616947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
    Goodacre SC; Street LJ; Hallett DJ; Crawforth JM; Kelly S; Owens AP; Blackaby WP; Lewis RT; Stanley J; Smith AJ; Ferris P; Sohal B; Cook SM; Pike A; Brown N; Wafford KA; Marshall G; Castro JL; Atack JR
    J Med Chem; 2006 Jan; 49(1):35-8. PubMed ID: 16392789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAR studies on a novel series of human cytomegalovirus primase inhibitors.
    Chen X; Adrian J; Cushing T; Dimaio H; Liang L; Mayorga V; Miao S; Peterson MG; Powers JP; Spector F; Stein C; Wright M; Xu D; Ye Q; Jaen J
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2188-92. PubMed ID: 17329103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).
    Christopher JA; Aves SJ; Bennett KA; Doré AS; Errey JC; Jazayeri A; Marshall FH; Okrasa K; Serrano-Vega MJ; Tehan BG; Wiggin GR; Congreve M
    J Med Chem; 2015 Aug; 58(16):6653-64. PubMed ID: 26225459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a]pyridines and [18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography.
    Fookes CJ; Pham TQ; Mattner F; Greguric I; Loc'h C; Liu X; Berghofer P; Shepherd R; Gregoire MC; Katsifis A
    J Med Chem; 2008 Jul; 51(13):3700-12. PubMed ID: 18557607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective MMP13 inhibitors.
    Li JJ; Johnson AR
    Med Res Rev; 2011 Nov; 31(6):863-94. PubMed ID: 20196103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of thieno[3,2-d]- pyrimidinones, thieno[3,2-d]pyrimidines and quinazolinones: conformationally restricted 17b-hydroxysteroid dehydrogenase type 2 (17b-HSD2) inhibitors.
    Perspicace E; Marchais-Oberwinkler S; Hartmann RW
    Molecules; 2013 Apr; 18(4):4487-509. PubMed ID: 23591928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties.
    Kirincich SJ; Xiang J; Green N; Tam S; Yang HY; Shim J; Shen MW; Clark JD; McKew JC
    Bioorg Med Chem; 2009 Jul; 17(13):4383-405. PubMed ID: 19482480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.